Skip to main content Accessibility help
×
Home

Interleukin-6 and total antioxidant capacity levels following N-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder

  • CC Bortolasci (a1), C Voigt (a2), A Turner (a1) (a3), M Mohebbi (a4), L Gray (a1), S Dodd (a1) (a3) (a5), K Walder (a1), M Berk (a1) (a3) (a6) (a5) (a7), SM Cotton (a5) (a7), GS Malhi (a8), CH Ng (a9), N Dowling (a9), J Sarris (a9) (a8) and OM Dean (a1) (a3) (a6)...

Abstract

Objective:

The aims of this study were to evaluate changes in inflammatory and oxidative stress levels following treatment with N-acetylcysteine (NAC) or mitochondrial-enhancing agents (CT), and to assess the how these changes may predict and/or moderate clinical outcomes primarily the Montgomery-Åsberg Depression Rating Scale (MADRS).

Methods:

This study involved secondary analysis of a placebo-controlled randomised trial (n=163). Serum samples were collected at baseline and week 16 of the clinical trial to determine changes in interleukin (IL)-6 and total antioxidant capacity (TAC) following adjunctive CT and/or NAC treatment, and to explore the predictability of the outcome or moderator effects of these markers.

Results:

In the NAC treated group, no difference was observed in serum IL-6 and TAC levels after 16 weeks of treatment with NAC or CT. However, results from a moderator analysis showed that in the CT group, lower IL-6 levels at baseline was a significant moderator of MADRS χ2 (df) = 4.90, p=0.027) and Clinical Global Impression-improvement (CGI-I, X2 (df)=6.28 p=0.012). In addition, IL-6 was a non-specific but significant predictor of functioning (based on the Social and Occupational Functioning Assessment Scale (SOFAS)), indicating that individuals with higher IL-6 levels at baseline had a greater improvement on SOFAS regardless of their treatment (p=0.023).

Conclusion:

Participants with lower IL-6 levels at baseline had a better response to the adjunctive treatment with the mitochondrial-enhancing agents in terms of improvements in MADRS and CGI-I outcomes.

Copyright

Corresponding author

*Corresponding author: Dr Olivia Dean, IMPACT SRC, School of Medicine, Deakin University, Kitchener House, P.O. Box 281, Geelong VIC 3220 Australia, +61 3 4215 3300, oliviad@barwonhealth.org.au.

Keywords

Interleukin-6 and total antioxidant capacity levels following N-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder

  • CC Bortolasci (a1), C Voigt (a2), A Turner (a1) (a3), M Mohebbi (a4), L Gray (a1), S Dodd (a1) (a3) (a5), K Walder (a1), M Berk (a1) (a3) (a6) (a5) (a7), SM Cotton (a5) (a7), GS Malhi (a8), CH Ng (a9), N Dowling (a9), J Sarris (a9) (a8) and OM Dean (a1) (a3) (a6)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.